Analysts issued an Underperform rating for shares while reluanching coverage of large-cap U.S. pharma and biotech names.

BofA reinstated coverage of Moderna (MRNA) with an Underperform rating and $41 price target calling it “a tough time to be a ...

On Tuesday, Moderna Inc (MRNA) stock saw a decline, ending the day at $41.51 which represents a decrease of $-4.14 or -9.07% from the prior close of $45.65. The stock opened at $45.36 and touched a ...

BofA has reinstated coverage of 11 large-cap pharmaceutical and biotech stocks, with Eli Lilly (NYSE:LLY), Gilead ...

Moderna (MRNA) shares tumble after Bank of America analysts reinstated its Underperform rating for the stock. In a broader note about the pharmaceutical and biotech spaces, Bank of America's team it's ...

BofA (BAC) analysts restarted their coverage on 11 large-capitalization pharmaceutical and biotech firms. The bad news was ...

BofA Securities notes that Moderna’s stock rose early Thursday but ended the day lower, likely due to slowing vaccine trends and uncertainty around the company’s respiratory vaccine lineup ...

BofA reinstated coverage of Pfizer (PFE) with a Neutral rating and $29 price target Uncertainty over COVID revenue streams plus a “tough” base ...

BofA analyst Curtis Nagle downgraded Duolingo (DUOL) to Neutral from Buy with a $375 price target Pick the best stocks and maximize your ...

Wall Street's main indexes closed lower on Tuesday as technology sector losses offset gains in communications services while ...